期刊文献+

局灶节段性肾小球硬化患者足细胞钙神经蛋白的表达 被引量:3

Expression of calcineurin on podocytes of patients with focal segmental glomerulosclerosis
下载PDF
导出
摘要 目的:观察成人局灶节段性肾小球硬化(focal segmental glomerulosclerosis,FSGS)患者足细胞钙神经蛋白的表达并探讨其意义。方法:选取临床表现为肾病综合征且经肾活检确诊的成人特发性FSGS63例,微小病变(minimal change disease,MCD)24例和肾移植供肾组织10例作为对照。免疫组化法检测肾组织钙神经蛋白A(CnA)异构体α、β、γ的表达。免疫荧光法行肾组织CnAα和synaptopodin双标记,并采用胶体金免疫电镜对肾小球CnAα的表达定位。两位病理医生分别盲法评分染色结果。结果:供肾组织肾小球CnAα、β、γ免疫组化染色均阴性,肾小管CnAα、β微弱表达,CnAγ阴性。26例FSGS患者肾小球足细胞CnAα表达上调,其阳性率为41.27%;而MCD患者肾小球CnAα阴性(P<0.01);两者肾小球CnAα、β、γ染色均阴性。足细胞CnAα阳性患者肾小管损伤指标尿视黄醇结合蛋白[20.91(0.17~54.37)mg/L]、血清肌酐[(128.18±56.58)μmol/L]高于阴性患者(P<0.05);两者间病理类型构成差异存在统计学意义(P<0.01);而年龄、性别、尿蛋白、尿N-乙酰-β-葡萄糖苷酶、血清白蛋白及胆固醇无统计学差异。塌陷型、细胞型、顶部型、门周型FSGS中足细胞CnAα阳性病例分别为5例(83.33%)、10例(66.67%)、8例(61.54%)、3例(20%),14例经典型FSGS患者均阴性。多因素Logistic回归分析示血清肌酐(OR4.855,P<0.01)、塌陷型(OR11.069,P<0.05)为FSGS患者足细胞CnAα过表达的主要相关因素。69.23%足细胞CnAα阳性患者肾小球syanptopodin表达减弱且不连续。结论:本研究首次发现部分FSGS患者足细胞上CnAα表达增强,这可能参与了FSGS的发病。FSGS与MCD患者足细胞CnAα的表达差异,提示二者发病机制不同。对临床怀疑FSGS而未见明确节段病变的患者,足细胞CnAα阳性有助于诊断。 Objective:To investigate whether calcineurin expression or not in podocytes of patients with focal segmental glomerulosclerosis (FSGS). Methodology:The renal ealeineurin subunit A α,β,γ isoforms (ChAα,β,γ) were detected by immunohistochemistry in sixty-three adult nephrotie, biopsy-proven idopathic FSGS patients. Twenty-four cases with minimal change disease ( MCD), and 10 donor renal grafts were regarded as control. CnAα and synaptopodin by immunofluorescence double staining was performed. The precise location of CnAα in glomeruli was confirmed by colloidal gold immunoeleetron microscopy. Immunostaining was scored by two pathologists in a double-blind manner. Results: Mild expression of CnAα and CnAα without CnAα, were found in renal tubules from donor renal grafts, while calcineurin wasn' t observed in glomeruli. CnAα expression was up-regulated in podocytes in cases with FSGS, however, CnAα and CnAα were negative. CnAα expression in podocytes increased in 26 (41.27%) FSGS cases, while all MCD were negative (P〈 0. 01 ). Serum creatinine, urinary rentiol binding protein, pathological variants were significant different between podocyte CnAα posivtie and negative FSGS cases ( P 〈 0.05 ). Podocyte CnAot posivte eases in Collapsing, Celluar, Tip, Hillar variant were 5 (83.33%), 10 (66. 67% ), 8 (61.54%) and 3 (20%), respectively, but none in NOS(P 〈0. 01 ). Serum ereatinine ( OR 4. 855, P 〈 0.01 ) , collapsing variant ( OR 11. 069, P 〈 0. 05 ) were critical factors for CnAαoverex-pression in podocytes of FSGS by Logistic regression. Synaptopodin was decreased and discontinued in 69. 23% cases with podocyte CnAα overexpression. Conclusion: We demonstrated that CnAα expresssion was upregulated in podocytes of some adult idopathic FSGS, which may be involved in the aggressive course. Differential expression of CnAα in podocytes suggests different pathogenic mechanism among FSGS variants and MCD. Detection of CnAα in podocytes is useful in distinction of FSGS versus MCD in renal biopsies without defining lesions.
出处 《肾脏病与透析肾移植杂志》 CAS CSCD 北大核心 2010年第4期301-308,共8页 Chinese Journal of Nephrology,Dialysis & Transplantation
关键词 局灶节段性肾小球硬化 微小病变 足细胞 钙神经蛋白 focal segmental glomerulosclerosis minimal change disease podocyte calcineurin
  • 相关文献

参考文献28

  • 1Thomas DB, Franceschini N, Hogan SL, et al. Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney Int, 2006,69 ( 5 ) :920 - 926.
  • 2张炯,刘志红,曾彩虹,张文,黎磊石.泼尼松治疗成人局灶节段性肾小球硬化的临床疗效[J].肾脏病与透析肾移植杂志,2009,18(1):13-19. 被引量:22
  • 3Choudhry S, Bagga A, Hari P, et al. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome : a randomized controlled trial. Am J Kidney Dis, 2009,53 (5) :760-769.
  • 4Hamasaki Y,Yoshikawa N, Hattori S, et al. Cyclosporine and steroid therapy in children with steroid-resistant nephrotic syndrome. Pediatr Nephrol,2009,24( 11 ) :2177 -2185.
  • 5Faul C, Donnelly M, Merscher-Gomez S, et al. The actin cytoskeleton of kidney podocytcs is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med ,2008,14 (9) :931 - 938.
  • 6D'Agati V. Pathologic classification of focal segmental glomerulosclerosis. Semin Nephrol,2003,23(2) :117 - 134.
  • 7Srivastava T, Garola RE, Whiting JM, et al, Synaptopodin expression in idiopathic nephrotic syndrome of childhood. Kidney Int,2001,59 (1) :118 -125.
  • 8Tumlin JA. Expression and function of calcineurin in the mammalian nephron: physiological roles, receptor signaling, and ion transport. Am J Kidney Dis, 1997,30 ( 6 ) :884 - 895.
  • 9Rusnak F, Mertz P. Calcineurin: form and function. Physiol Rev, 2000,80(4) :1483 - 1521.
  • 10Hata R, Masumura M, Akatsu H, et al. Up-regulation of calcineurin Abeta mRNA in the Alzheimer's disease brain: assessment by cDNA microarray. Biochem Biophys Res Commun, 2001, 284 ( 2 ) : 310 -316.

二级参考文献20

  • 1Li LS, Liu ZH. Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. Kidney Int, 2004, 66 (3) : 920 - 923.
  • 2Braun N, Sehmutzler F, Lange C, et al. Immunosuppressive treatment for focal segmental glomerulosclerosis in adults( Intervention review). Cochrane Database of Systematic Reviews,2008, (3) : 1 - 34.
  • 3Korbet S, Schwartz M, Lewis E. Primary focal segmental glomerulo- sclerosis: clinical course and response to therapy. Am J Kidney Disease, 1994, 23(6): 773-783.
  • 4Korbet SM. Treatment of primary focal segmental glomerulosclerosis. Kidney Int, 2002, 62 : 2301 - 2310.
  • 5Cattran DC, Rao P. Long-term outcome in children and adult with classic focal segmental glomerulosclerosis. Am J Kidney Dis, 1998, 32 : 72 - 79.
  • 6Rydel JJ, Korbet SM, Borok RZ, et al. Focal segmental glomerular sclerosis in adults: presentation, course and response to treatment. Am J Kidney Dis, 1995,25: 534-542.
  • 7Pontieelli C, Villa M, Banfi G, et al. Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis? Am J Kidney Dis, 1999, 34:618 -625.
  • 8Schwartz MM, Evans J, Bain R, et al. Focal segmental glornerulo- sclerosis: prognositic implications of the cellular lesion. J Am Soc Nephrol, 1999, 10:1900-1907.
  • 9Meyrier A, Noel LH, Auriehe P, et al. Long-term renal tolerance of cyclosporine A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Societe de Nephrologie. Kidney Int, 1994, 45 : 1446 - 1456.
  • 10Korbet SM. Primary focal segmental glomerulosclerosis. J Am Soc Nephrol, 1998, 9 : 1333 - 1340.

共引文献21

同被引文献16

  • 1崔敏,刘志红,朱丽晶,陈惠萍,曾彩虹,周虹,黎磊石.乙型肝炎病毒感染肾炎患者肾组织病毒抗原和复制中间体的检测及其意义[J].肾脏病与透析肾移植杂志,2004,13(4):301-308. 被引量:29
  • 2陈燕.月经周期相关性蛋白尿及血压异常[J].肾脏病与透析肾移植杂志,2005,14(3):295-300. 被引量:2
  • 3崔昭 赵明辉 王素霞.肾脏有免疫复合物沉积的抗肾小球基底膜病的临床病理特点[J].中华肾脏病杂志,2004,20:1-5.
  • 4Faul C, Donnelly M, MerscherGomez S, et al. The actin cytoskeleton of kidney podocytes is a direct target of the an- tiproteinuric effect of cyclosporine A [ J ]. Nat Med, 2008, 14:931 -938.
  • 5Wang Y, Jarad G, Tripathi P, et al. Activation of NFAT signaling in podocytes causes glomerulosclerosis [ J ]. J Am Soc Nephrol, 2010, 21 : 1657 - 1666.
  • 6Cui Z, Zhao J, Jia XY, et al. anti-glomerular basement membrane disease: outcomes of different therapeutic regi- mens in a large singlecenter Chinese cohort study [ J ]. Medicine (Baltimore), 2011, 90: 303- 311.
  • 7Bariety J, Bruneval P, Meyrier A, et al. Podocyte involve- ment in human immune crescentic glomerulonephritis [ J ]. Kidney Int, 2005, 68:1109-1119.
  • 8Le Hir M, Keller C, Eschmann V, et al. Podocyte bridges between the tuft and Bowman's capsule: an early event in experimental crescentic glomerulonephritis [ J ]. J Am Soc Nephrol, 2001, 12 : 2060 - 2071.
  • 9Gooch JL. An emerging role for calcineurin Aalpha in the development and function of the kidney [ J ]. Am J Physiol Renal Physiol, 2006, 290 : F769 - 776.
  • 10刘志红,黎磊石.局灶节段性肾小球硬化研究的新方法、新观点[J].肾脏病与透析肾移植杂志,2009,18(1):1-2. 被引量:15

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部